盘龙药业: 2025年半年度报告摘要

Core Viewpoint - The report highlights the financial performance of Shaanxi Panlong Pharmaceutical Group Co., Ltd. for the first half of 2025, showing a significant increase in revenue and a slight rise in net profit, while cash flow from operating activities has decreased substantially [2][4]. Financial Performance - The company's operating revenue for the reporting period reached CNY 574,023,000.14, representing a 26.06% increase compared to CNY 455,356,633.75 in the same period last year [2]. - The net profit attributable to shareholders of the listed company was CNY 60,135,150.47, which is a 0.81% increase from CNY 59,653,263.68 in the previous year [2]. - The net cash flow from operating activities was CNY 62,620,899.02, showing a significant decrease of 43.66% from CNY 111,157,587.41 in the previous year [2]. - Basic and diluted earnings per share remained unchanged at CNY 0.57 [2]. Assets and Equity - Total assets at the end of the reporting period amounted to CNY 2,362,246,494.51, reflecting a 3.61% increase from CNY 2,280,023,009.54 at the end of the previous year [4]. - The net assets attributable to shareholders of the listed company were CNY 1,664,436,104.93, which is a 1.79% increase from CNY 1,635,217,029.35 [4]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,406 [4]. - The largest shareholder, Xie Xiaolin, holds 34.99% of the shares, amounting to 37,189,932 shares [4].